CAMBRIDGE, Mass., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the company will webcast presentations at its Research and Development (R&D) Day on Wednesday, October 15, 2014, from 9:00 a.m. to approximately 12:00 p.m. EDT in New York City.
Presentations from members of Agios’ management team are expected to include reviews of the company’s approach to R&D, the science behind its two lead medicines in development for cancer – AG-221 and AG-120, which are first-in-class, oral, selective, potent inhibitors of the mutated IDH2 protein and IDH1 protein, respectively – and the science behind its lead investigational medicine, AG-348, for a rare genetic disorder of metabolism. AG-348 is a novel, first-in-class, orally available activator of pyruvate kinase-R (PKR) for the treatment of pyruvate kinase (PK) deficiency. Presentations will also include a review of the diseases these investigational medicines aim to treat, including hematologic malignancies, solid tumors and PK deficiency. Speakers scheduled to present include:
- David Schenkein, M.D., Chief Executive Officer
- Scott Biller, Ph.D., Chief Scientific Officer
- Chris Bowden, M.D., Chief Medical Officer
- Sam Agresta, M.D., Vice President, Head of Clinical Development
- Eyal Attar, M.D., Medical Director
Agios invites the public and media to listen to the presentations via a live webcast that can be accessed under “Events & Presentations” in the Investors and Media section of the company’s website at agios.com. The presentations are scheduled to begin at approximately 9:00 a.m. Eastern Daylight Time. A replay of the webcast will be archived on the Agios website for approximately 30 days following the presentation.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel medicines to treat cancer and rare genetic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead investigational medicines in cancer metabolism and rare genetic disorders of metabolism in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging the company’s knowledge of metabolism, biology and genomics. For more information, please visit Agios’ website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ expectations and beliefs about: the potential of IDH1/IDH2 and pyruvate kinase R mutations as therapeutic targets; the potential benefits of its product candidates targeting IDH1/IDH2 or pyruvate kinase R mutations, including AG-221, AG-120 and AG-348; and its plans and strategies. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs, including risks and uncertainties relating to: Agios’ ability to successfully commence and complete necessary preclinical and clinical development of its product candidates; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; Agios’ ability to maintain its collaboration with third parties on acceptable terms; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; unplanned cash requirements and expenditures; competitive factors; Agios’ ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios’ ability to obtain the substantial additional capital required to execute its plans and strategies; and general economic and market conditions. These and other risks are described in greater detail in filings that Agios makes with the SEC from time to time including risks described under the caption “Risk Factors” included in Agios’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Agios Pharmaceuticals, Inc. Lora Pike lora.pike@agios.com T: 617-649-8608
Help employers find you! Check out all the jobs and post your resume.
